← Leaderboards
Jurgen Bernd Bulitta
State University Of New York At Buffalo
$13,249,415
Attributed
$15,812,207
Total exposure
6
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.2M · FY2017–25$5M$3.8M$2.5M$1.3M$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$19,254,717 · 5
FDA$1,205,223 · 2
By mechanism
R01$13,058,482 · 3
P01$6,196,235 · 2
U01$1,205,223 · 2
Top collaborators
- Brian Tsuji5 shared
- Guenther Hochhaus3 shared
- Ashley Brown1 shared
- George Louis Drusano1 shared
- Arnold Louie1 shared
Most similar at State University Of New York At Buffalo
Same institution · by research overlap
- Brian Tsuji$5,737,626
- Yanan Zhao$1,596,741
Others in their field
Other Emerging Leaders on “Prospective”
- Peter W Pisters · University Of Tx Md Anderson Can Ctr$56,084,949
- Michael Dignam · National Institute Of Allergy And Infectious Diseases$31,845,607
- Stephen F Kry · University Of Tx Md Anderson Can Ctr$28,689,457
- Ellen Gould Chadwick · Harvard University D/B/A Harvard School Of Public Health$25,473,113
- Olwen Hahn · Brigham And Women'S Hospital$23,582,395
- Julie Ake · National Institute Of Allergy And Infectious Diseases$22,000,000
Research focus
ProspectiveBeta-LactamaseInsightDoseInfectionBeta-LactamsResistanceSuperbugBacteriaReceptorPenetrationAntibioticsSiteCombatInnovationMortalityCombined AntibioticsPharmaceutical PreparationsMolecularMembraneRegimenPharmacologyPreventIn Vitro
Grant awards (22)
Translational development of new agents alone and in combination to combat Gram-negative pathogens important in Ventilator- Associated Bacterial Pneumonia: Leveraging the Gram-negative toolbox that is$2,339,559
P01 · FY2025 · AI
Project 1 Mechanistic Project$696,393
P01 · FY2025 · AI · contact PI
Translational development of new agents alone and in combination to combat Gram-negative pathogens important in Ventilator- Associated Bacterial Pneumonia: Leveraging the Gram-negative toolbox that is$2,308,174
P01 · FY2024 · AI
Project 1 Mechanistic Project$852,109
P01 · FY2024 · AI · contact PI
Novel Strategies for Antibiotic Combinations to Combat Gram-negative Superbugs$751,348
R01 · FY2024 · AI
Feasibility of predicting regional lung exposure from systemic pharmacokinetic data of generic OIDPs via population pharmacokinetic modeling and non-compartmental approaches$249,998
U01 · FY2024 · FD · contact PI
Novel Strategies for Antibiotic Combinations to Combat Gram-negative Superbugs$764,100
R01 · FY2023 · AI
Feasibility of predicting regional lung exposure from systemic pharmacokinetic data of generic OIDPs via population pharmacokinetic modeling and non-compartmental approaches$249,998
U01 · FY2023 · FD · contact PI
Combating resistant superbugs by understanding the molecular determinants of target site penetration and binding$1,068,186
R01 · FY2022 · AI · contact PI
Novel Strategies for Antibiotic Combinations to Combat Gram-negative Superbugs$783,756
R01 · FY2022 · AI
Next-generation combination dosing strategies to combat resistant Acinetobacter baumannii$657,531
R01 · FY2022 · AI · contact PI
Combating resistant superbugs by understanding the molecular determinants of target site penetration and binding$1,107,656
R01 · FY2021 · AI · contact PI
Novel Strategies for Antibiotic Combinations to Combat Gram-negative Superbugs$782,154
R01 · FY2021 · AI
Next-generation combination dosing strategies to combat resistant Acinetobacter baumannii$674,050
R01 · FY2021 · AI · contact PI
Combating resistant superbugs by understanding the molecular determinants of target site penetration and binding$1,110,059
R01 · FY2020 · AI · contact PI
Novel Strategies for Antibiotic Combinations to Combat Gram-negative Superbugs$839,004
R01 · FY2020 · AI
Next-generation combination dosing strategies to combat resistant Acinetobacter baumannii$649,808
R01 · FY2020 · AI · contact PI
Combating resistant superbugs by understanding the molecular determinants of target site penetration and binding$1,134,590
R01 · FY2019 · AI · contact PI
Next-generation combination dosing strategies to combat resistant Acinetobacter baumannii$688,839
R01 · FY2019 · AI · contact PI
Combating resistant superbugs by understanding the molecular determinants of target site penetration and binding$1,307,630
R01 · FY2018 · AI · contact PI
Next-generation combination dosing strategies to combat resistant Acinetobacter baumannii$739,771
R01 · FY2018 · AI · contact PI
Comprehensive evaluation of formulation effects on metered dose inhaler performan$705,227
U01 · FY2017 · FD